Sno	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	16/NW/0787	216022	ALBATROSS	Number Agreed	2	2	Date Agreed	15/06/2017	4	22/06/2017	4	Recruitment Finished
2	16/SC/0341	204761	EZH-203	Range Agreed	4	5	Date Agreed	31/10/2017	1	17/05/2017	1	Withdrawn By Sponsor
3	15/NW/0098	138128	A Phase 2, Multicenter, Open-Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, Safety And Activity Of Azacitidine And To Compare Azacitidine To Historical Controls In Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Synd	Number Agreed	1	1	Date Agreed	31/03/2017	0	12/09/2017	0	Recruitment Finished
4	14/NE/1050	155345	Einstein Junior Phase III - Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboemb	Number Agreed	3	3	Date Agreed	27/05/2018	3	25/05/2017	3	Recruitment Finished
5	14/WS/1078	143053	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis	Number Agreed	2	2	Date Agreed	30/06/2017	0	30/06/2017	0	Recruitment Finished
6	15/YH/0402	187262	CNS Unmet Medical Need in Mucopolysaccharidosis: A Phase 2 Safety and Pharmacokinetics Study of Ataluren (COMPASS)	Number Agreed	1	1	Date Agreed	30/11/2016	1	13/04/2017	1	Withdrawn By Sponsor
7	15/LO/1226	163213	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia	Range Agreed	1	2	Date Agreed	30/04/2017	0	19/05/2017	0	Withdrawn By Sponsor
8	15/NW/0067	166982	ASCEND-Peds (A phase 1/2, multi-center, open-label, ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of recombinant human acid sphingomyelinase in pediatric patients aged <18 years	Number Agreed	2	2	Date Agreed	31/03/2016	2	12/04/2017	2	Recruitment Finished
9	14/LO/1514	150294	An Open Label Study to Assess the Safety and Efficacy of COR?003 (2S, 4R?Ketoconazole) in the Treatment of Endogenous Cushing?s Syndrome	Number Agreed	2	2	Date Agreed	30/09/2017	1	09/06/2017	1	Recruitment Finished
10	14/SC/1340	151325	A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease Phase II Study (TV5600-CNS	Range Agreed	4	12	Date Agreed	07/04/2017	2	04/04/2017	3	Recruitment Finished
11	14/SS/1087	164169	A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease	Range Agreed	1	5	Date Agreed	30/04/2017	5	30/04/2017	5	Recruitment Finished
12	15/NW/0229	170151	Worldwide Randomized Antibiotic Envelope Infection Prevention Trial	Range Agreed	30	100	Date Agreed	30/06/2018	52	25/07/2017	52	Recruitment Finished
13	13/NE/0005	100377	A prospective, non-interventional registry providing continuing evaluation and periodic reporting of product safety, effectiveness and patient outcomes across Medtronic market released products within diabetes, cardiac rhythm disorders, urological,	Range Agreed	5	25	Date Agreed	01/09/2018	18	28/04/2017	18	Recruitment Finished
14	15/LO/0528	174833	Evaluating the use of wearable technology and smart phone apps to monitor paediatric diseases	Range Agreed	5	10	Date Agreed	01/06/2017	23	31/07/2017	26	Recruitment Finished
15	16/SC/0039	188354	A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis	Range Agreed	2	5	Date Agreed	31/05/2017	1	06/09/2017	1	Recruitment Finished
16	13/LO/1522	137260	LTS13632 (A long-term study to assess the ongoing safety and efficacy of olipudase alfa in patients with acid sphingomyelinase deficiency)	Range Agreed	1	2	Date Agreed	31/08/2017	2	30/08/2017	2	Recruitment Finished

Sno	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17	16/LO/1854	184654	A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Ar	Range Agreed	50	100	Date Agreed	30/09/2017	56	19/05/2017	56	Recruitment Finished
18	17/YH/0083	220358	A Randomized Controlled Trial of Gentle Touch/Early Massage with a New Wash and Lotion Regimen for Improved Skin Barrier Strength, Parental Bonding, and Physical Development in Newborn Babies	Number Agreed	30	30	Date Agreed	30/09/2017	32	30/09/2017	32	Recruitment Finished
19	15/NW/0821	191169	Oricol	Number Agreed	20	20	Date Agreed	31/07/2017	30	21/09/2017	30	Recruitment Finished
20	13/EE/0326	137999	Revacept	Range Agreed	64	80	Date Agreed	30/05/2017	19	30/05/2017	19	Recruitment Finished
21	15/LO/0681	174407	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients with Early Manifest Huntington?s Diseas	Number Agreed	4	4	Date Agreed	30/04/2017	4	30/04/2017	4	Recruitment Finished
22	15/WS/0061	178522	A Randomized, Doubleblind, Eventdriven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and SignificantCoronary Artery Dise	Number Agreed	5	5	Date Agreed	15/10/2017	1	31/07/2017	1	Recruitment Finished
23	15/SC/0456	174561	AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI-PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULTPATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS	Range Agreed	1	3	Date Agreed	30/09/2017	0	29/09/2017	0	Withdrawn By Sponsor
24	16/ES/0001	193859	A Phase 3, randomized, double-blind, placebo-controlled, multicentre study to investigate the efficacy and safety of Mongersen (GED-0301) for the treatment of subjects with active Crohn's Disease	Number Agreed	3	3	Date Agreed	31/03/2017	2	20/10/2017	2	Withdrawn By Sponsor
25	16/WS/0005	193858	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN?S DISEASE	Range Agreed	1	3	Date Agreed	30/11/2017	1	20/10/2017	1	Withdrawn By Sponsor
26	17/LO/0212	221502	An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumabgiven as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C (ORION-3)	Range Agreed	1	3	Date Agreed	31/07/2017	2	13/06/2017	2	Recruitment Finished
27	17/SC/0236	226436	PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY	Range Agreed	1	6	Date Agreed	31/12/2017	6	27/11/2017	6	Recruitment Finished
28	16/SC/0542	208245	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITYOF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULARDEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY	Range Agreed	1	4	Date Agreed	31/03/2018	2	20/11/2017	2	Recruitment Finished
29	17/SC/0236	226436	PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY	Number Agreed	1	1	Date Agreed	31/12/2017	1	22/08/2017	1	Recruitment Finished
30	16/ES/0001	193859	Revolve (Celgene GED-0301-CD-002)	Number Agreed	3	3	Date Agreed	29/11/2017	0	19/10/2017	0	Withdrawn By Sponsor
31	17/NW/0019	212375	A3921192 SOAR ? A Study of a Once-A-day investigational drug for RA	Number Agreed	2	2	Date Agreed	21/03/2019	0	31/10/2017	0	Withdrawn By Sponsor
32	12/WM/0341	108069	A double-blind, randomised, placebo-controlled, multicentre study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardio	Number Agreed	1	1	Date Agreed	26/01/2015	0	10/04/2017	1	Recruitment Finished

Sno	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
33	13/WM/0235	126333	ATrial FibrillaTion ProgrESsion Trial	Number Agreed	1	1	Date Agreed	01/08/2017	0	27/02/2018	5	Withdrawn By Sponsor
34	13/LO/0867	126972	Double-blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy fo	Number Agreed	4	4	Date Agreed	30/03/2018	15	05/01/2018	15	Recruitment Finished
35	15/NW/0698	183781	A twenty six week, randomized, openlabel, 2 arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo? compared to standard of care insulin, in basal insulin treated patients with uncontrolled	Number Agreed	4	4	Date Agreed	07/10/2016	0	20/12/2017	0	Recruitment Finished
36	17/SC/0016	218645	A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable PleuralMesothelioma	Range Agreed	4	6	Date Agreed	30/06/2018	3	22/02/2018	3	Recruitment Finished
37	14/NI/1038	153733	A Prospective Randomized Controlled Study Evaluating the Safety and Efficacy of EVICEL? used for Suture-Line Sealing in Dura-Mater Closure during Paediatric Neurosurgical Cranial Procedures	Range Agreed	1	6	Date Agreed	01/05/2019	2	05/01/2018	2	Recruitment Finished
38	15/LO/1289	181953	An international, multicenter, randomized, double-blind, placebo-controlledphase 3 trial investigating the efficacy andsafety of Rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheralartery disease underg	Number Agreed	4	4	Date Agreed	04/09/2017	9	08/12/2017	13	Recruitment Finished
39	15/NW/0827	181796	A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients withRelapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation	Number Agreed	4	4	Date Agreed	28/02/2017	0	20/02/2018	0	Recruitment Finished
40	16/LO/0361	193839	Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults	Number Agreed	4	4	Date Agreed	08/12/2016	7	27/11/2017	7	Recruitment Finished
41	17/NW/0145	217442	Longitudinal study of chronic wounds using novel wound measurement technologies	Range Agreed	10	15	Date Agreed	01/05/2018	16	31/01/2018	16	Recruitment Finished
42	17/NE/0136	224520	A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B	Number Agreed	1	1	Date Agreed	31/10/2017	1	18/10/2017	1	Recruitment Finished
43	16/LO/0794	202764	RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of ranibizumab compared with laser therapy for the treatment of infants born prematurely with retinopathy of prematurity	Number Agreed	2	2	Date Agreed	12/10/2016	2	30/06/2017	2	Recruitment Finished
44	16/WM/0170	195010	ISIS 304801-CS7 -An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)	Range Agreed	1	2	Date Agreed	31/12/2017	5	31/12/2017	5	Recruitment Finished